Inari Medical, Inc. - NARI STOCK NEWS

Inari Medical (NASDAQ: NARI) announced positive results from the 800-patient FLASH registry, presented at the 2022 TCT conference. The study, evaluating the FlowTriever system in treating pulmonary embolism (PE), reported a low major adverse event rate of 1.8% and 30-day all-cause mortality of just 0.8%. The findings underscore FlowTriever's strong safety profile and clinical effectiveness, suggesting it may enhance PE treatment outcomes. Inari aims to continue developing high-quality evidence through ongoing studies like the FLAME registry and PEERLESS trial.

Inari Medical, Inc. (NASDAQ: NARI) announced its first Analyst and Investor Day scheduled for September 15, 2022, at its headquarters in Irvine, California. The event will involve a comprehensive update on the company’s business progress and future plans via a webcast set to begin at 9 a.m. Pacific Time. Participation is open to interested stakeholders, who can pre-register through a provided link. Additionally, a replay of the presentation will be available for 90 days on the company's Investor Relations website.

Inari Medical, Inc. (NASDAQ: NARI) announced the presentation of three new data sets from pivotal clinical studies at the 2022 TCT and VEINS conferences. The FLASH registry will showcase results from 800 patients treated with the FlowTriever system, focusing on safety and clinical outcomes, presented on September 18. The CLOUT registry results involving 500 patients will be shared on October 30-31, evaluating the ClotTriever system's effectiveness. A comparison of CLOUT data with ATTRACT outcomes will also be highlighted. These studies aim to refine the treatment standards for venous thromboembolism (VTE).

Inari Medical (NASDAQ: NARI) announced the upcoming enrollment of the DEFIANCE trial, a randomized controlled study aimed at assessing the effectiveness of the ClotTriever System for treating iliofemoral deep vein thrombosis (DVT) compared to traditional anticoagulation therapy. This trial will involve 300 patients across 60 centers globally. DEFIANCE is expected to set new treatment standards and reduce post-thrombotic syndrome risks. It follows the PEERLESS trial, further bolstering Inari's commitment to pioneering clinical research in vascular treatments.

Inari Medical, Inc. (NASDAQ: NARI) announced its participation in two upcoming investor conferences. The first is the Wells Fargo Healthcare Conference on September 9, 2022, at 8:35 a.m. Eastern Time in Boston, MA, featuring a fireside chat. The second is the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:10 a.m. Eastern Time in New York, NY, also a fireside chat. Interested parties can access live audio webcasts through the company’s website.

Drew Hykes will replace Bill Hoffman as Chief Executive Officer of Inari Medical (NASDAQ: NARI), effective January 1, 2023. Hykes, who has been with Inari since 2017, previously served as Chief Operating Officer and Chief Commercial Officer. Under his leadership, Inari has experienced significant growth, evolving from a startup to a public company with over 1,000 employees. The company also announced its second quarter 2022 financial results, highlighting its minimally invasive thrombectomy devices aimed at treating venous diseases.

Inari Medical reported a strong second quarter in 2022, achieving $92.7 million in revenue, a 46% year-over-year increase. The company expanded its U.S. commercial footprint to over 270 territories and received FDA clearance for two new products. Gross profit stood at $82.4 million, resulting in an 88.8% gross margin. However, the operating expenses surged to $91.7 million, leading to a net loss of $10.2 million. Inari reaffirmed its full-year revenue guidance of $360 million to $370 million.

Inari Medical (NASDAQ: NARI) will announce its Q2 2022 financial results on August 3, 2022. A conference call is scheduled for 2:00 PM PT to discuss these results and recent highlights. The company specializes in medical devices for treating venous diseases, offering minimally invasive catheter-based solutions like the ClotTriever and FlowTriever systems, which are FDA-cleared and CE-marked for clot removal. Investors can join the conference call after registering.

Okami Medical Inc. has received FDA 510(k) clearance for its LOBO-7 and LOBO-9 Vascular Occluders, enhancing its LOBO portfolio designed for peripheral vascular interventions. These new devices, along with existing LOBO-3 and LOBO-5, enable efficient blood vessel occlusions, crucial for procedures requiring rapid response in trauma cases. According to the company's leadership, this expansion emphasizes their commitment to innovation in vascular embolization, potentially improving patient outcomes and procedural efficiency.